HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH

Their core work

Helios Dr. Horst Schmidt Kliniken Wiesbaden is a large private hospital complex in Wiesbaden, Germany, operated under the HELIOS Kliniken Group — one of Europe's largest private hospital operators. In H2020 research, this institution contributes as a clinical site: providing patient access, clinical trial infrastructure, and medical expertise to large pan-European research networks. Their participation in c4c and EJP RD shows a specific orientation toward underserved patient populations — children and people with rare diseases — where real-world clinical settings and access to patients are the core asset they bring to research consortia. They are not a research lab; they are a functioning hospital that opens its clinical environment to EU-funded science.

What they specialise in

How they've shifted over time

Their first project (c4c, 2018) was rooted in the practicalities of clinical trial delivery for children — drug development, medicines, infrastructure, regulatory and educational best practice. This is classic hospital-as-trial-site work. Their second project (EJP RD, 2019) shifted toward the rare disease field and brought in a more data-centric vocabulary: omics, FAIR data, shared access, public-private partnerships, and patient empowerment. The trend suggests the institution is moving beyond pure clinical site operations toward engagement with research data infrastructure and the broader ecosystem around underserved patient groups.

This hospital is positioning itself within two growing EU research priorities — paediatric medicine and rare diseases — and appears to be developing competence in research data standards (FAIR, omics), which suggests future engagement in data-sharing consortia and translational research networks.

How they like to work

Helios Wiesbaden has participated exclusively as a consortium partner, never as coordinator, across both projects. Both c4c and EJP RD are massive pan-European programmes with dozens to hundreds of partners, meaning this hospital is one node in very large clinical networks rather than a driver of research direction. Working with them likely means accessing their clinical capacity, patient cohorts, and medical expertise within a structured multi-partner programme — they are not a partner that drives agendas but one that reliably delivers a clinical function.

Despite only two projects, this organisation has touched 192 unique consortium partners across 35 countries — a direct consequence of participating in two of the largest clinical research networks in H2020. Their network is European in reach but driven by the programmes they joined rather than independent relationship-building.

What sets them apart

What distinguishes Helios Dr. Horst Schmidt Kliniken Wiesbaden is their identity as a large-volume private hospital with demonstrated willingness to embed in EU research consortia — a combination that is less common than university hospitals in research settings. For consortia that need a German clinical site with access to paediatric or rare disease patient populations outside the academic hospital system, this institution fills a specific gap. Their HELIOS Group affiliation also means potential scale-up across a network of over 80 hospitals if needed for multi-site studies.

Highlights from their portfolio

• c4c
  A flagship EU effort to build a pan-European clinical trial network for children — one of the largest and most complex paediatric medicine initiatives in H2020, running to 2025.
• EJP RD
  The European Joint Programme on Rare Diseases is a €110M+ COFUND programme coordinating over 130 institutions across Europe, placing this hospital within one of the most politically significant rare disease research programmes of the decade.